Objectives. This study sought to determine the safety of deferral of percutaneous transluminal coronary angioplasty (PTCA) of angiographically intermediate but functionally nonsignificant stenosis, as assessed by coronary pressure measurement and myocardial fractional flow reserve (FFR myo ).
Patients with chest pain, a coronary artery stenosis and easily inducible ischemia have a higher risk for a coronary event than patients with a similar angiographic degree of stenosis but without inducible ischemia or only ischemia at high levels of exercise. It is therefore justifiable to treat angiographically moderate but functionally significant stenoses (1) (2) (3) .
However, clinical decision making in patients with persistent typical or atypical chest pain and angiographically intermediate stenosis, but no objective proof of inducible ischemia, remains challenging. In those patients, despite repeated negative or inconclusive noninvasive stress tests, the question of whether their complaints are related to that specific stenosis often remains.
Although intermediate stenosis poses a certain prognostic risk for a coronary event, only few quantitative data on the extent of this risk are available (4) . Even less is known about whether this risk can be reduced by an intervention that has an inherent risk of initiating the deteriorating process of plaque activation and restenosis (5, 6) . For that reason, reliable methods for evaluating the functional significance of intermediate lesions in the catheterization laboratory would be helpful in making the decision to perform dilation. If functionally significant (i.e., capable of inducing reversible ischemia), the respective stenosis could be dilated; if not, percutaneous transluminal coronary angioplasty (PTCA) could be deferred.
As we recently showed (7), myocardial fractional flow reserve (FFR myo ), calculated from coronary pressure measurements, is a useful index for determining the functional severity of an intermediate coronary stenosis. Several studies (8, 9) have convincingly demonstrated that an FFR myo of 0.75 accurately discriminates lesions capable of inducing reversible ischemia at exercise from those not capable of doing so.safety and long-term outcome of deferring a coronary intervention in patients initially referred for PTCA of an intermediate coronary stenosis, but in whom the intervention was deferred on the basis of a sufficiently high FFR myo Ն0.75.
Methods
FFR myo . The FFR myo of a coronary artery is defined as the ratio between maximal achievable blood flow to its dependent myocardium and the hypothetically maximal achievable blood flow to that same territory if the supplying artery were completely normal (10) . Contrary to absolute coronary flow reserve, FFR myo is independent of changes in systemic blood pressure and heart rate and is not affected by conditions known to increase baseline myocardial blood flow (8, 11) . In addition, FFR myo takes into account collateral blood flow to the dependent myocardium (12) . FFR myo can be easily and rapidly obtained during cardiac catheterization as the ratio between distal hyperemic coronary pressure, measured by a pressure guide wire, and aortic pressure, measured by the guiding catheter (8) . The normal value of this index is 1.0 and because there is no need for a control artery, it is also applicable in multivessel disease (8) .
Patients. Between May 1993 and May 1997 at our centers in Aalst and Eindhoven, guide wire-based coronary pressure measurements to determine FFR myo were performed in Ͼ600 patients, either at diagnostic or at interventional catheterization. From this patient group all records were reviewed to select the first 100 patients who fulfilled the following inclusion criteria: 1) Patients were referred for intervention of one stenosis in the mid or proximal part of a native coronary artery; 2) the myocardial territory dependent on the stenosed target vessel was normokinetic, as assessed by visual estimation of the ventriculogram; and 3) the planned intervention was deferred on the basis of a pressure-derived FFR myo Ն0.75, determined during the control angiogram just before the planned PTCA.
Coronary catheterization and coronary pressure measurement. In all patients, at the time of the planned PTCA, a 6F to 8F guiding catheter was introduced into the femoral artery and advanced into the ostium of the target vessel. Intracoronary or sublingual nitroglycerin and 10,000 U of heparin were administered just before control angiograms were made, according to local routine. Thereafter, a pressure monitoring guide wire (Pressure Guide, Radi Medical Systems, Uppsala, Sweden) was zeroed, calibrated and advanced through the catheter into the coronary artery and positioned distal to the stenosis, as previously described (8) . Next, maximal myocardial hyperemia was induced by adenosine, either as an intracoronary bolus of 12 to 20 g or by intravenous infusion in a femoral vein at an infusion rate of 140 g/kg body weight per min for a duration of 2 to 4 min (13) (14) (15) . Examples of the angiogram and pressure recordings from one study patient are shown in Figures 1 and  2 , respectively.
FFR myo was then calculated at maximal hyperemia from the simultaneously recorded aortic (P a ) and distal coronary pressure (P d ) by the ratio FFR myo ϭ P d /P a , as described previously (8) . Figure 1 . The pressure wire is positioned across the stenosis, and no gradient is observed at rest (RESTING). After start of intravenous adenosine infusion (140 g/kg per min), a pressure gradient gradually develops, and at steady state maximal coronary hyperemia (HYPER-EMIA), FFR myo is calculated by the P d /P a ratio, which equals 82/93 ϭ 0.89. This value is well above the cutoff point of 0.75 for reversible ischemia; therefore, no intervention was performed.
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Quantitative coronary arteriography. Quantitative coronary arteriographic (QCA) analysis of the control cine angiograms, obtained just before the planned intervention in preferably two orthogonal projections by the cardiovascular angiography analysis system (16, 17) , was performed. Using the guiding catheter as a scaling device, the reference diameter, minimal lumen diameter, percent diameter stenosis and percent area stenosis of the target lesion were assessed. The values presented are the average of the orthogonal projections.
Follow-up and clinical events. Follow-up clinical data were obtained in all patients by patient interview and by written correspondence with the cardiologist who was presently treating or had last treated the patient. Clinical events were mutually exclusive and were defined in the following ranking order as death, myocardial infarction, unstable angina, coronary artery bypass graft surgery and coronary angioplasty. Death was considered cardiac related, unless proved otherwise. Coronary events were subclassified into target vessel related or target vessel unrelated.
The decision not to perform the planned angioplasty required extensive explanation to the patient and the referring cardiologist. In particular, it was explained that the decision to defer the intervention was based on coronary pressure measurements indicating adequate myocardial perfusion and that the operator had concluded that the lesion could not be held responsible for the patient's chest pain. Decisions regarding medical treatment of the patient after deferral of PTCA were left to the referring physician.
Statistics. Data are reported as number of patients and mean value Ϯ SD. Differences between mean CCS class and mean number of antianginal drugs used at baseline and at follow-up were determined using the Wilcoxon test. Differences between mean percent diameter stenosis and FFR myo in the event-free and event group were assessed using the t test. A p value Ͻ 0.05 was considered significant, and all tests were two-tailed. Patient curves for freedom from death and coronary events were constructed according to the method of Kaplan and Meier (18) .
Results
Baseline characteristics. The clinical characteristics of the study patients are shown in Table 1 . At least one noninvasive stress test had been performed in 64 patients, of whom 28 had a positive result for ischemia. Therefore, in a total of 72 patients, noninvasive stress tests for ischemia were negative (n ϭ 30), inconclusive (n ϭ 6) or not available (n ϭ 36). In those patients, the decision to schedule PTCA had been based solely on persistent chest pain and the presence of an angiographically suspect lesion. Ten patients were in CCS class I but were referred for an intervention on the basis of coincident positive stress test results and the presence of an intermediate stenosis.
Angiographic characteristics and FFR myo . The lesion characteristics, as well as the results of the pressure measurements, are shown in Table 2 . The target lesion was located in the proximal or midsection of the left anterior descending coronary artery in 64 patients, the left circumflex coronary artery in 10 and the right coronary artery in 26. Quantitative coronary angiographic analysis of the reference diameter of the adjacent normal segment, minimal stenosis lumen diameter, percent diameter stenosis and percent area stenosis resulted in average values of 3.17 Ϯ 0.67 mm, 1.68 Ϯ 0.45 mm, 46.9 Ϯ 9.4% and 68.5 Ϯ 10.5%, respectively (Table 2) . In 40 patients, the percent diameter stenosis was Ͼ50%. In 35 patients, the minimal lumen diameter was Ͻ1.5 mm. The average FFR myo was 0.87 Ϯ 0.07 (range 0.75 to 1.00). The average peak hyperemic transstenotic pressure gradient was 12 Ϯ 6 mm Hg (range 0 to 24).
Procedural safety and follow-up. There were no procedural complications related to catheterization or coronary pressure measurements. Complete clinical follow-up was obtained in all patients. The average follow-up period was 18 Ϯ Data presented are mean value Ϯ SD, range or number of patients. Ca ϭ calcium; CABG ϭ coronary artery bypass graft surgery; CAD ϭ coronary artery disease; CCS ϭ Canadian Cardiovascular Society; Hx ϭ history; LVEF ϭ left ventricular ejection fraction; MI ϭ myocardial infarction; Prev ϭ previous; PTCA ϭ percutaneous transluminal coronary angioplasty.
13 months (range 3 to 42) and was Ͼ6 months in 79 patients. During the follow-up period (Table 3) , two patients died of noncardiac causes after 3 and 10 months, respectively. The first was a 49-year old man with atypical complaints and a mild aortic stenosis (mean gradient 12 mm Hg), who committed suicide 3 months after catheterization. The second was a 77-year old man who died of a gastric cancer. In this patient with chest pain and known coronary disease, gastrectomy was considered. Intracoronary pressure measurements were performed to evaluate the need for preoperative PTCA of the stenosis. PTCA was deferred on the basis of an FFR myo of 0.89. No cardiac-related deaths occurred.
In eight patients coronary events occurred, four of which were target vessel related (Table 3 ). The characteristics of these patients are shown in Table 4 . The average interval to a target vessel-related incident was 27 months, whereas the average interval to incidents not related to the target vessel was 11 months. Only two coronary events occurred within 6 months after deferral, and both were unrelated to the target vessel. There was no difference in QCA variables (p ϭ 0.909) or in FFR myo (p ϭ 0.374) at the initial assessment between patients with an event at follow-up and the remaining group.
The average CCS class in the event-free group (90 patients) decreased from 2.0 Ϯ 1.2 at baseline to 0.7 Ϯ 0.9 at follow-up (p Ͻ 0.0001). The average number of antianginal drugs used in these 90 patients decreased from 2.4 Ϯ 1.2 at baseline to 1.9 Ϯ 1.2 at follow-up (p ϭ 0.0022). At follow-up, 81 patients were in CCS class I or had no chest pain.
Survival and event-free survival. As analyzed by the Kaplan-Meier method, at 42 months the percent estimated survival (ϮSEM) after deferral of PTCA was 97 Ϯ 2%; survival free from death or target vessel-related events was 84 Ϯ 7%; and survival free from death or any coronary event was 78 Ϯ 7% (Fig. 3) .
Discussion
Favorable outcome without intervention. The present study indicates that it is safe to defer angioplasty of an intermediate stenosis if that stenosis has no physiologic importance, as assessed by pressure-derived FFR myo Ն0.75.
No cardiac-related deaths occurred in our deferred group, and during an average follow-up period of 18 months, a target vessel-related event occurred only in 4 of 100 patients. Only one patient experienced a myocardial infarction after 26 months because of disease progression in the target vessel. The average reference diameter of the coronary arteries in the present study was Ͼ3 mm, indicating that these were all large vessels and that the favorable outcome was not due to inclusion of smaller vessels that would have had a good outcome in any case.
Rationale of coronary pressure measurement. FFR myo is a functional index of epicardial stenosis severity, and it has been well demonstrated (7, 8) that the cutoff value of 0.75 discriminates between functionally significant and nonsignificant stenoses. The diagnostic accuracy of FFR myo for this purpose is 93% and is higher than any other single noninvasive stress test if performed alone (7) . Therefore, in our catheterization laboratories, it is standard practice to determine the FFR myo if there is reasonable doubt that the culprit lesion scheduled for PTCA is actually causing the complaints. Such is often the case when the lesion is moderate and the exercise test not clearly positive or when the complaints are atypical. FFR myo is easily obtained just before PTCA by using a pressure guide wire instead of a regular guide wire and by measuring distal coronary pressure and aortic pressure simultaneously at maximal hyperemia.
In patients with persistent chest pain, coronary angiography is often performed despite the absence of objective proof of ischemia (7, 19) . It has been shown (20) that in a randomly selected group of asymptomatic 60-year old men, the preva- Data presented are mean value Ϯ SD, range or number of patients. Pts ϭ patients; UA ϭ unstable angina; other abbreviations as in Table 1. lence of apparently significant coronary stenoses is 20%. Therefore, one must assume that in a number of such patients, the presence of a lesion may be coincidental and that a direct relation between the angiographic lesion and the chest pain is unclear. Nevertheless, in clinical practice, PTCA of the intermediate lesion is often performed despite the absence of objective proof of ischemia (19) . This practice has been defended in that even if that lesion is not related to the patient's chest pain, PTCA would be justified by the "plaquesealing" concept (21) . However, this concept is unproved, and in so performing PTCA, a previously stable (and functionally not significant) lesion might be activated and a deleterious "restenosis" process triggered. In fact, it is expected that in 20% to 30% of such patients, a clinically relevant restenosis will occur within 6 months. It is therefore unclear whether the risk of dilating a functionally nonsignificant but angiographically intermediate stenosis outweighs the risk of leaving such a lesion untreated.
Evidence of reversible ischemia as a prerequisite for performing PTCA. In the present study, 72 patients had been scheduled for angioplasty only on the basis of clinical and visual angiographic criteria. Stress testing in these patients was either negative, inconclusive or not performed. Although our study cohort was restricted to patients with intermediate stenoses, their data are comparable to those of a general PTCA population, as reported by Topol et al. (19) , indicating that in the United States, Ͼ60% of coronary interventions are performed without objective proof of reversible ischemia. By QCA, 40 of 100 stenoses in the present study group appeared to be Ͼ50% in diameter stenosis, the anatomic cutoff value generally accepted for discriminating between "significant" and "nonsignificant" lesions. Such lesions would have been routinely dilated had only angiographic criteria been applied (22, 23) . However, by our measuring FFR myo , a number of unnecessary PTCAs were avoided in this group.
Although the rate of clinical events in the present study is markedly lower than that usually reported after angioplasty, it may be argued that in recent angioplasty trials, lesions undergoing a coronary intervention, were on average more symptomatic, had a larger degree of obstruction as assessed by quantitative coronary angiography and were all associated with positive exercise tests. Nevertheless, it is noteworthy that in those studies a coronary event rate of ϳ30% was reported within 12 months after balloon angioplasty alone and ϳ15% after stenting (24) . In the present study, no target vesselrelated events occurred within the first 6 months of follow-up, and only in 10% of this study group did events occur after an average follow-up of 18 months. This event rate is only slightly above the coronary event rate found in an asymptomatic 60-year old population of ϳ2% to 3%/year and is in accordance with previous studies (7, (25) (26) (27) in similar patient groups where intervention was deferred on the basis of physiologic measurements of either coronary blood flow velocity or coronary pressure. In 28 patients the pre-PTCA exercise test was positive despite a FFR myo Ͼ0.75. Exercise-induced spasm may have played a role in some patients, and the exercise test could have been false positive in others. It is well known that the accuracy of exercise testing in patients with moderate stenosis is low and that false positive results may occur in up to 20% of these patients (7). Moreover, as described earlier, in 10 of these 28 patients no complaints were present, and the indication for angiography, which revealed the intermediate stenosis, had been the positive exercise test itself. In those patients the rate of false positive exercise tests must have been higher than usual (27) . Two of these 28 patients experienced a coronary event, respectively, at 20 and 24 months, both target vessel related. This long event-free interval suggests that these events may have been related to the natural progression of atherosclerotic disease rather than to incorrect initial diagnosis.
In the 90 event-free patients, anginal class improved significantly at follow-up despite a decrease in the average number of antianginal medications taken by these patients. This improvement is possibly related to patient reassurance by our explaining that the lesion was not clinically important and that the chest pain could very well be of other than cardiac origin (7, 25) . This decrease in symptoms after reassurance supports the idea that in many of these patients the chest pain was not caused by the coronary lesion, underlining that deferral of the planned PTCA had been the correct decision.
Indications for coronary pressure measurement before PTCA. As stated earlier, in our catheterization laboratories coronary pressure measurement and determination of FFR myo are routinely performed in patients in whom reasonable doubt exists about the significance of coronary lesions, either at diagnostic angiography or just before planned PTCA. This is the case in ϳ10% of our patients and relates to intermediate stenosis, equivocal noninvasive stress test results or atypical complaints. Other indications are facilitating the decision to perform either PTCA of one or two vessels or bypass surgery of three or more vessels, depending on the significance of the respective lesions, or to decide whether minimal invasive surgery of a left anterior descending coronary artery stenosis is a reasonable option for multivessel disease (28) . The technique of coronary pressure measurement is easily applicable during a routine procedure, and additional costs are U.S.$500 for the pressure wire in cases of PTCA and an additional U.S.$150 in a diagnostic case for the Y-connector and a (generally 6F or 7F) guiding catheter. If FFR myo Ͼ0.75, intervention of the respective lesion is always deferred. Therefore, selection bias was unlikely in the present study.
Conclusions.
Because this study is retrospective and nonrandomized and does not provide comparative data from a control group of patients in whom angioplasty was actually performed, it is impossible to establish the clinical event rate that would have occurred had angioplasty actually been performed. Nevertheless, it can be concluded that in patients with chest pain who are scheduled for PTCA of an intermediate coronary stenosis, deferral of PTCA on the basis of an FFR myo Ͼ0.75 is safe, irrespective of the noninvasive stress test result, and is associated with a very low coronary event rate of ϳ5%/year, much lower than expected had PTCA been performed in all patients. To confirm these observations, a large randomized, prospective study is currently underway.
